Integración de la Medicina Biorreguladora de Sistemas durante quimioterapia standard basada en bleomicina, etopósido y platino, en cáncer testicular metastásico. Reporte de un caso.

AbstractIntroduction: Metastatic testicular germ cell tumors are potentially curable with cisplatin-based chemotherapy. Evidence regarding systems bioregulatory medicine (SBM) as supportive care during BEP chemotherapy is limited. This report describes its incorporation into the management of a single case, without establishing antitumor efficacy or a causal effect on treatment tolerability.Case presentation: A 34-year-old man had a mixed germ cell tumor of the left testis, pathological category pT2, with lymphovascular invasion, retroperitoneal lymphadenopathy, and bilateral pulmonary nodules consistent with metastatic disease. The prechemotherapy alpha-fetoprotein (AFP) level was 44.4 ng/mL. Clinical stage III was documented.Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy were documented, starting on December 2 and 30, 2024, January 27, 2025, and February 24, 2025, at institutional 28-day intervals. No additional delays, dose omissions, or dose reductions due to toxicity were recorded. Systems bioregulatory medicine (SBM) was administered before, during, and after chemotherapy as complementary supportive care.Results: AFP levels decreased to 10.7, 1.13, and 1.00 ng/mL before the second, third, and fourth cycles, respectively, and measured 1.63 ng/mL in September 2025. The highest documented toxicity was grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. ECOG performance status remained at 0, and Karnofsky performance status ranged from 90% to 100%. Post-treatment assessment on May 6, 2025, showed resolution of the pulmonary and nodal lesions, with no pathological metabolic activity on PET/CT.Conclusion: Adherence to the institutional treatment schedule, mild toxicity, and a favorable response were observed during BEP chemotherapy with conventional supportive care and SBM. The single-case design and modified treatment schedule preclude attributing these outcomes to the complementary intervention or establishing the absence of pharmacological interactions.

Authors

Publication Details

Journal
Figshare
Published
2026-11-12
DOI
https://doi.org/10.6084/m9.figshare.34988941
Primary Topic
Complementary and Alternative Medicine Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Integración de la Medicina Biorreguladora de Sistemas durante quimioterapia standard basada en bleomicina, etopósido y platino, en cáncer testicular metastásico. Reporte de un caso.

Carmen Rivas, Luis Martínez, Paula Martínez
Figshare
Complementary and Alternative Medicine Studies
preprint

Integración de la Medicina Biorreguladora de Sistemas durante quimioterapia standard basada en bleomicina, etopósido y platino, en cáncer testicular metastásico. Reporte de un caso.

Carmen Rivas, Luis Martínez, Paula Martínez
preprint en

Abstract

AbstractIntroduction: Metastatic testicular germ cell tumors are potentially curable with cisplatin-based chemotherapy. Evidence regarding systems bioregulatory medicine (SBM) as supportive care during BEP chemotherapy is limited. This report describes its incorporation into the management of a single case, without establishing antitumor efficacy or a causal effect on treatment tolerability.Case presentation: A 34-year-old man had a mixed germ cell tumor of the left testis, pathological category pT2, with lymphovascular invasion, retroperitoneal lymphadenopathy, and bilateral pulmonary nodules consistent with metastatic disease. The prechemotherapy alpha-fetoprotein (AFP) level was 44.4 ng/mL. Clinical stage III was documented.Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy were documented, starting on December 2 and 30, 2024, January 27, 2025, and February 24, 2025, at institutional 28-day intervals. No additional delays, dose omissions, or dose reductions due to toxicity were recorded. Systems bioregulatory medicine (SBM) was administered before, during, and after chemotherapy as complementary supportive care.Results: AFP levels decreased to 10.7, 1.13, and 1.00 ng/mL before the second, third, and fourth cycles, respectively, and measured 1.63 ng/mL in September 2025. The highest documented toxicity was grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. ECOG performance status remained at 0, and Karnofsky performance status ranged from 90% to 100%. Post-treatment assessment on May 6, 2025, showed resolution of the pulmonary and nodal lesions, with no pathological metabolic activity on PET/CT.Conclusion: Adherence to the institutional treatment schedule, mild toxicity, and a favorable response were observed during BEP chemotherapy with conventional supportive care and SBM. The single-case design and modified treatment schedule preclude attributing these outcomes to the complementary intervention or establishing the absence of pharmacological interactions.

Figshare
Good health and well-being
Complementary and Alternative Medicine Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon